FOR IMMEDIATE RELEASE
March 2026
NomosLogic Launches Dendrite Lite and Defines a New Category:
Deterministic Clinical Genomics
Utah-based company delivers the first consumer-accessible, deterministic pharmacogenomic platform — powered by the same clinical engine now available to health systems and clinical partners
SALT LAKE CITY, Utah — NomosLogic Inc., a Utah-based clinical genomics infrastructure company, today announced the public launch of Dendrite Lite, a consumer-facing genomic health platform that delivers deterministic pharmacogenomic findings to anyone with an existing DNA file. Simultaneously, NomosLogic announced the availability of its Clinical Standalone engine for health system and clinical partners — the same deterministic infrastructure that powers Dendrite Lite, available for enterprise clinical deployment.
The launch marks the first time a deterministic clinical genomics engine — one that produces the same auditable output every time from the same input, with findings traceable to FDA, CPIC, and PharmGKB evidence sources — has been made accessible to consumers at scale.
"I didn't build NomosLogic because I saw a market opportunity. I built it because my own DNA told me something my doctors hadn't. My CFTR variant functions as a tumor suppressor in the GI tract. Combined with confirmed polyps and celiac disease, the genomic picture was clear — and it changed my surveillance plan entirely. I didn't find out I was sick. I found out I was informed. No one should have to build their own engine to get that clarity." — Matt Hardy, Founder & CEO, NomosLogic Inc.
The Problem NomosLogic Was Built to Solve
Medicine has been practiced for centuries on a fundamental assumption: that population-level averages apply to individual patients. Standard drug doses are built for a statistical abstraction — an average person who does not exist. The result is a system where the same medication heals one patient, fails another, and harms a third — not because of physician error, but because the individual's genomic profile was never part of the equation.
The science to change this has existed for decades. FDA-documented drug-gene interactions, CPIC prescribing guidelines, PharmGKB pharmacogenomic annotations — the evidence base is established, peer-reviewed, and clinically validated. What has not existed, until now, is the infrastructure to resolve that evidence against an individual's specific genetic profile at consumer scale, in plain language, in minutes.
Probabilistic AI systems have attempted to fill this gap — with mixed results. Systems that approximate outputs rather than compute them cannot be the foundation for clinical decisions that have correct answers. A patient's CYP2C19 status either makes their proton pump inhibitor ineffective at standard dosing, or it does not. That is not a probabilistic question. It is a computable one.
Defining the Category: Deterministic Clinical Genomics
NomosLogic introduces Deterministic Clinical Genomics as a distinct category — differentiated from consumer ancestry testing, probabilistic AI health tools, and traditional clinical laboratory services by three defining characteristics:
Deterministic output — the same DNA input always produces the same clinical output. Every finding is reproducible, auditable, and traceable to its evidence source. The engine does not guess. It computes.
Clinical-grade evidence — findings are cross-referenced against FDA drug-gene interaction databases, CPIC prescribing guidelines, PharmGKB annotations, and NomosLogic's proprietary Hardy Bridge variant mapping system. Tier 1 findings carry established clinical guidelines. Tier 2 findings are clearly identified as research-context associations.
Consumer accessibility — for the first time, the same quality of genomic resolution available in clinical research and enterprise health systems is accessible to any individual with an existing consumer DNA file from 23andMe, AncestryDNA, or MyHeritage.
"Every American is being dosed for an average person who doesn't exist. Your CFTR variant may be silently raising your GI cancer risk. Your DPYD status may make a standard chemotherapy dose dangerous. Your CYP2C19 gene may mean the medication you've been taking for years has never fully worked. This isn't fringe science. It's FDA-validated pharmacogenomics — and most Americans have never had access to it. That changes today." — Matt Hardy, Founder & CEO, NomosLogic Inc.
Dendrite Lite: Consumer Genomic Intelligence, Now Available
Dendrite Lite is available today at lite.nomoslogic.com. The platform accepts existing DNA files from 23andMe, AncestryDNA, and MyHeritage — no new testing required. Reports are generated in under 130 seconds and delivered as a permanent, patient-owned document with no subscription and no recurring charges.
Dendrite Lite is offered at three tiers:
What's Included
Essential - $99 one-time
Critical drug-gene interactions, medication safety alerts, full PDF report — permanently owned by the patient
Complete - $149 one-time
Everything in Essential plus complete drug-gene analysis, dosing guidance, health trait insights, and ancestry-related health factors
Premium - $249 one-time
Everything in Complete plus Chiron — NomosLogic's AI health agent — auto-updated reports, medication interaction checker, and priority support
Chiron, NomosLogic's AI health agent available in the Premium tier, interprets deterministic TRINITY engine output in plain language — direct without being alarming, warm without being patronizing, technically precise without being inaccessible. Chiron does not make clinical recommendations. It translates what the deterministic engine computed into language patients can bring to their healthcare providers.
Clinical Standalone: The Same Engine for Health Systems and Clinical Partners
NomosLogic's Clinical Standalone engine is available now for health systems, clinical practices, longevity clinics, and specialty care partners. The same deterministic infrastructure that powers Dendrite Lite — cross-referencing patient DNA against 1,257,095 clinical logic objects and 496,805 Hardy Bridge proprietary variant mappings — is available for clinical deployment without the consumer-facing interface.
Clinical partners can submit patient DNA files directly and receive structured pharmacogenomic reports including drug-gene interaction findings, prescriber quick reference tables tiered by evidence level, and recommended clinical actions — all in under 130 seconds per patient.
NomosLogic is concurrently developing Dendrite Clinical, a SMART on FHIR EHR-embedded version of the platform that surfaces pharmacogenomic findings natively within the clinical workflow. Epic App Orchard registration is in progress. Health systems interested in piloting Dendrite Clinical are encouraged to contact NomosLogic directly.
"The clinical engine and the consumer platform are the same infrastructure. That's intentional. A finding that is clinically defensible in a health system should be the same finding a patient can access from their own DNA file at home. We built one engine. We made it accessible at both ends of the care continuum." — Matt Hardy, Founder & CEO, NomosLogic Inc.
Platform Architecture: Built for Clinical Defensibility
NomosLogic's platform is architected around a core principle: clinical decisions require correct answers, not probabilistic approximations. Key platform characteristics include:
Deterministic output guarantee — identical DNA input always produces identical clinical output. Every finding carries a full audit provenance trail.
496,805 Hardy Bridge proprietary variant mappings — resolving consumer DNA nomenclature to clinical-grade findings across 40+ nomenclature systems, 14,000x faster than manual curation.
1,257,095 clinical logic objects — encoding FDA drug-gene interactions, CPIC prescribing guidelines, PharmGKB annotations, and Hardy Bridge-validated findings.
362+ FDA drug labels mapped with documented drug-gene interaction requirements.
Three-Outcome genomic resolution — every variant position is classified as POSITIVE, NEGATIVE_HC (high-confidence reference), or NO_CALL. Clinical ambiguity is surfaced, never silently assumed.
HIPAA-hardened Double-Blind PII vaulting — patient identity and genomic data stored in separately encrypted vaults with dual-key authorization.
Under 130 seconds from DNA upload to complete pharmacogenomic report.
About the Founder
Matt Hardy is the Founder and CEO of NomosLogic Inc. With over 30 years of software engineering experience spanning health plan integrations, EDI systems, and enterprise technology infrastructure, Hardy brings deep technical expertise and personal conviction to the problem of genomic access.
Hardy's own genomic profile was the founding catalyst. His CFTR variant — which functions as a tumor suppressor in the gastrointestinal tract — combined with confirmed polyps and celiac disease, presented a GI cancer surveillance picture his clinical team had not fully connected. His DPYD variant independently revealed that a standard chemotherapy drug would have been dangerous at normal dosing. Neither finding required new testing. Both were already in his DNA. He built NomosLogic to make that kind of clarity available to everyone. Hardy is an active member of the American College of Medical Genetics (ACMG) and a recognized voice in the clinical genomics community.
Availability
Dendrite Lite — Available now at lite.nomoslogic.com. Compatible with 23andMe, AncestryDNA, and MyHeritage DNA files. One-time purchase, no subscription. Reports permanently owned by the patient.
Clinical Standalone — Available now for qualified health system and clinical partners. Contact NomosLogic directly for onboarding.
Dendrite Clinical (SMART on FHIR) — In development. Epic App Orchard registration in progress. Health system pilot inquiries welcome.
About NomosLogic Inc.
NomosLogic Inc. is a Utah-based clinical genomics infrastructure company delivering deterministic Logic-as-a-Service (LaaS). The company's mission is to ensure that every individual has access to the genomic intelligence that makes precision medicine possible — regardless of whether they are a patient in a health system or a consumer at home. NomosLogic's platform resolves consumer and clinical DNA against the largest proprietary variant mapping system and clinical rules engine available, producing pharmacogenomic findings with full audit provenance in under 130 seconds. NomosLogic is headquartered in Salt Lake City, Utah.
Media Contact
Matt Hardy
Founder & CEO, NomosLogic Inc.
(801) 810-7009
NomosLogic Inc. · Salt Lake City, Utah · www.nomoslogic.com
